Cargando…

Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease: Associations with laboratory findings, comorbidities, and medications

OBJECTIVES: To show the levels of vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) in patients with end-stage renal disease (ESRD) and to show the associations with clinical findings such as demographic features, laboratory findings, comorbi...

Descripción completa

Detalles Bibliográficos
Autores principales: Erturk, Ismail, Yesildal, Fatih, Acar, Ramazan, Ozgurtas, Taner, Saglam, Kenan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Saudi Medical Journal 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058753/
https://www.ncbi.nlm.nih.gov/pubmed/29915853
http://dx.doi.org/10.15537/smj.2018.6.22024
_version_ 1783341755998928896
author Erturk, Ismail
Yesildal, Fatih
Acar, Ramazan
Ozgurtas, Taner
Saglam, Kenan
author_facet Erturk, Ismail
Yesildal, Fatih
Acar, Ramazan
Ozgurtas, Taner
Saglam, Kenan
author_sort Erturk, Ismail
collection PubMed
description OBJECTIVES: To show the levels of vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) in patients with end-stage renal disease (ESRD) and to show the associations with clinical findings such as demographic features, laboratory findings, comorbidities, and medications. METHODS: A total of 73 people, consisting of patients with ESRD (n=38) and healthy subjects (n=35) in Gulhane Education and Research Hospital, Ankara, Turkey, were included in this cross-sectional study between the years 2011 and 2013. Blood samples were obtained and plasma VEGF, sVEGFR-1 analyzes were performed. RESULTS: The VEGF level of ESRD group was not significantly higher (0.280±0.264) than the control group (0.321±0.210) (p=0.475). The sVEGFR-1 level of ESRD group was significantly higher (0.217±0.135) than the control group (0.068±0.047) (p<0.001). The correlation between VEGF and sVEGFR-1 was significant and negative (r=-0.246, p=0.036). Average VEGF level of ESRD patients using recombinant human erythropoietin (rhEPO) was significantly higher (0.567±0.28) than the ESRD patients not using rhEPO (0.246±0.24) (p=0.025). CONCLUSION: Our study is the first showing the significance of sVEGFR-1 in ESRD patients, and associations with comorbidities, medications. Especially our finding of rhEPO and VEGF may illuminate a reasonable positive effect of rhEPO on angiogenesis. Soluble vascular endothelial growth factor receptor-1 and VEGF may be important markers in the pathophysiology of ESRD.
format Online
Article
Text
id pubmed-6058753
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Saudi Medical Journal
record_format MEDLINE/PubMed
spelling pubmed-60587532018-07-27 Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease: Associations with laboratory findings, comorbidities, and medications Erturk, Ismail Yesildal, Fatih Acar, Ramazan Ozgurtas, Taner Saglam, Kenan Saudi Med J Original Article OBJECTIVES: To show the levels of vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) in patients with end-stage renal disease (ESRD) and to show the associations with clinical findings such as demographic features, laboratory findings, comorbidities, and medications. METHODS: A total of 73 people, consisting of patients with ESRD (n=38) and healthy subjects (n=35) in Gulhane Education and Research Hospital, Ankara, Turkey, were included in this cross-sectional study between the years 2011 and 2013. Blood samples were obtained and plasma VEGF, sVEGFR-1 analyzes were performed. RESULTS: The VEGF level of ESRD group was not significantly higher (0.280±0.264) than the control group (0.321±0.210) (p=0.475). The sVEGFR-1 level of ESRD group was significantly higher (0.217±0.135) than the control group (0.068±0.047) (p<0.001). The correlation between VEGF and sVEGFR-1 was significant and negative (r=-0.246, p=0.036). Average VEGF level of ESRD patients using recombinant human erythropoietin (rhEPO) was significantly higher (0.567±0.28) than the ESRD patients not using rhEPO (0.246±0.24) (p=0.025). CONCLUSION: Our study is the first showing the significance of sVEGFR-1 in ESRD patients, and associations with comorbidities, medications. Especially our finding of rhEPO and VEGF may illuminate a reasonable positive effect of rhEPO on angiogenesis. Soluble vascular endothelial growth factor receptor-1 and VEGF may be important markers in the pathophysiology of ESRD. Saudi Medical Journal 2018-06 /pmc/articles/PMC6058753/ /pubmed/29915853 http://dx.doi.org/10.15537/smj.2018.6.22024 Text en Copyright: © Saudi Medical Journal http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Erturk, Ismail
Yesildal, Fatih
Acar, Ramazan
Ozgurtas, Taner
Saglam, Kenan
Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease: Associations with laboratory findings, comorbidities, and medications
title Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease: Associations with laboratory findings, comorbidities, and medications
title_full Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease: Associations with laboratory findings, comorbidities, and medications
title_fullStr Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease: Associations with laboratory findings, comorbidities, and medications
title_full_unstemmed Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease: Associations with laboratory findings, comorbidities, and medications
title_short Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease: Associations with laboratory findings, comorbidities, and medications
title_sort vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease: associations with laboratory findings, comorbidities, and medications
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058753/
https://www.ncbi.nlm.nih.gov/pubmed/29915853
http://dx.doi.org/10.15537/smj.2018.6.22024
work_keys_str_mv AT erturkismail vascularendothelialgrowthfactorandsolublevascularendothelialgrowthfactorreceptor1inpatientswithendstagerenaldiseaseassociationswithlaboratoryfindingscomorbiditiesandmedications
AT yesildalfatih vascularendothelialgrowthfactorandsolublevascularendothelialgrowthfactorreceptor1inpatientswithendstagerenaldiseaseassociationswithlaboratoryfindingscomorbiditiesandmedications
AT acarramazan vascularendothelialgrowthfactorandsolublevascularendothelialgrowthfactorreceptor1inpatientswithendstagerenaldiseaseassociationswithlaboratoryfindingscomorbiditiesandmedications
AT ozgurtastaner vascularendothelialgrowthfactorandsolublevascularendothelialgrowthfactorreceptor1inpatientswithendstagerenaldiseaseassociationswithlaboratoryfindingscomorbiditiesandmedications
AT saglamkenan vascularendothelialgrowthfactorandsolublevascularendothelialgrowthfactorreceptor1inpatientswithendstagerenaldiseaseassociationswithlaboratoryfindingscomorbiditiesandmedications